1. Scrip
  2. >>Business
  3. >>Deals

Coherus Continues Funding IO Ambitions By Offloading Biosimilars

 
• By Joseph Haas

Coherus agreed to sell its biosimilar of Amgen’s Neulasta to Intas in a deal that will clear significant near-term debt and provide funds for a label-expansion strategy for its PD-1 agent Loqtorzi.

Coherus sold off its Neulasta biosimilar to further focus on immuno-oncology (Shutterstock)

Coherus BioSciences has been transitioning from a focus on biosimilars to developing and commercializing its own immuno-oncology therapies – led by anti-PD-1 agent Loqtorzi (toripalimab-tpzi) – and it took major steps toward further clearing its portfolio and resolving some debt issues with a $483.4m sale on 2 December of Udenyca (pegfilgrastim-cbqv), its biosimilar of Amgen’s Neulasta, to Intas Pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

First Quarter M&A Activity Rose On The Strength Of Three Deals

 
• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

More from Strategy

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

First Quarter M&A Activity Rose On The Strength Of Three Deals

 
• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market